Denice Tsao-Wei
Overview
Explore the profile of Denice Tsao-Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jackovich A, Gitlitz B, Tiu-Lim J, Duddalwar V, King K, El-Khoueiry A, et al.
Oncotarget
. 2024 Jul;
15:444-458.
PMID: 38985143
Objective: Patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) after primary local therapy have low response rates with cetuximab, systemic chemotherapy or check point inhibitor therapy....
2.
Hogarty M, Ziegler D, Franson A, Chi Y, Tsao-Wei D, Liu K, et al.
Br J Cancer
. 2024 Jan;
130(5):788-797.
PMID: 38200233
Background: MYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to determine the maximum tolerated dose (MTD) of DFMO, an Odc inhibitor,...
3.
Nawrocki S, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5087-5103.
PMID: 37812476
Purpose: Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity. We conducted an investigator-initiated clinical trial to evaluate PELA in combination with dexamethasone...
4.
OConnell C, Baer M, Orskov A, Saini S, Duong V, Kropf P, et al.
Clin Cancer Res
. 2022 Oct;
28(24):5306-5316.
PMID: 36222848
Purpose: We hypothesized that resistance to hypomethylating agents (HMA) among patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) would be overcome by combining a programmed death-ligand 1 antibody...
5.
Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, et al.
J Clin Oncol
. 2022 Aug;
41(3):640-650.
PMID: 35984996
Purpose: Patients with metastatic urothelial carcinoma have poor prognosis after failure of standard first-line chemotherapy. Immune check point programmed death 1-programmed death ligand 1 antibodies have low response rates and...
6.
Dubois S, Granger M, Groshen S, Tsao-Wei D, Ji L, Shamirian A, et al.
J Clin Oncol
. 2021 Jul;
39(31):3506-3514.
PMID: 34270348
Purpose: I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens was likely associated with the highest true...
7.
Barzi A, Choi A, Tsao-Wei D, Iqbal S, El-Khoueiry A, Agafitei D, et al.
Oncologist
. 2020 Jul;
25(12):e1879-e1885.
PMID: 32649004
Lessons Learned: Neoadjuvant bevacizumab with modified FOLFOX7 without radiation failed to meet the goal of pathological complete response rate; however, the low number of recurrence and disease-free survival in this...
8.
Xiong S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, Gaur R, Epstein A, et al.
BMC Cancer
. 2019 Nov;
19(1):1114.
PMID: 31729966
We investigated the association of LHR expression in epithelial ovarian cancer (OC) with clinical and pathologic characteristics of patients. LHR expression was examined immunohistochemically using tissue microarrays (TMAs) of specimens...
9.
Tuscano J, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev A, et al.
Clin Cancer Res
. 2019 Sep;
25(23):7004-7013.
PMID: 31481504
Purpose: Based on the potential for ipilimumab (I) to augment T-cell activation, we hypothesize that ipilimumab would augment the efficacy of rituximab (R) in patients with relapsed/refractory (R/R) CD20non-Hodgkin's lymphoma...
10.
Barzi A, Lara Jr P, Tsao-Wei D, Yang D, Gill I, Daneshmand S, et al.
Cancer
. 2019 Aug;
125(21):3853-3863.
PMID: 31398279
Background: Several studies have investigated the relationship between experience measured by caseload and oncological outcomes, economics, and access to care for prostate cancer care. Oncological outcomes have been limited to...